Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RR News 6 October 2025 - 9 January 2026

Richtech Robotics (RR) stock rises again in premarket as CES “Dex” demo keeps traders watching

Richtech Robotics (RR) stock rises again in premarket as CES “Dex” demo keeps traders watching

Richtech Robotics shares rose 1% in premarket trading Friday after a 14.9% surge Thursday, driven by attention from a CES demo of its humanoid robot “Dex.” The company is operating under an SEC extension to file its annual report, projecting a wider net loss and $5.1 million in fiscal 2025 revenue. Investors are watching for CES updates and signs of new deals as the event ends.
9 January 2026
··
Richtech Robotics (RR) Stock Jumps on Robotics Policy Buzz and AI Deals – Latest News and 2025 Outlook (Dec. 4, 2025)

Richtech Robotics (RR) Stock Jumps on Robotics Policy Buzz and AI Deals – Latest News and 2025 Outlook (Dec. 4, 2025)

Richtech Robotics Inc. (NASDAQ: RR) has stormed back into the market’s spotlight this week. After a brutal stretch of volatility, the small‑cap service‑robotics company is suddenly one of the biggest winners in the robotics trade, powered by rumors of new U.S. policy support, fresh AI partnerships, and ambitious product launches. Below is a structured look at where the stock trades today, what has just happened around the company, and how analysts now frame the risk–reward profile as of December 4, 2025. Where Richtech Robotics Stock Stands Today As of the close on Wednesday, December 3, 2025, Richtech Robotics’ Class B
4 December 2025
···
Richtech Robotics (NASDAQ: RR) Deep Dive — Why This Small‑Cap Robot Maker Is Turning Heads and Stirring Controversy in 2025

Richtech Robotics (NASDAQ: RR) Deep Dive — Why This Small‑Cap Robot Maker Is Turning Heads and Stirring Controversy in 2025

Key Facts (as of 6 Oct 2025) Company Overview Founded in Nevada and headquartered in Las Vegas, Richtech Robotics Inc. designs and sells AI‑driven service robots for hospitality, retail, healthcare and industrial clients. It is an early mover in Robots‑as‑a‑Service (RaaS), offering robots on subscription contracts rather than one‑off hardware salesinvesting.com. The product portfolio includes: Richtech claims to have deployed over 400 robots across U.S. restaurants, retail stores, hotels, healthcare facilities, casinos, senior living homes and factoriesir.richtechrobotics.com. Notable clients include Texas Rangers’ Globe Life Field, Golden Corral, Hilton, Sodexo and Boyd Gamingnasdaq.com. The company’s mission is to solve labour shortages through automation and to build “the
6 October 2025
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop